Ligand Pharmaceuticals Incorporated (LGND): Technical Analysis and analyst Ratings


Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) changes shares on Tuesday trading session, with a change of -0.97% or -$1.15 shares. The trading starts at $122.32 and closed at $119.08 throughout the day. The trading session low price was $116.75 and day high was $122.965 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.41 million while its average volume is 324.51K. In other hand, the LGND market cap reached to $2.05B. While, its current target price is $179.67.

On June 15, 2020, BRIEF-Ligand Announces An Expansion Of Vernalis Collaboration With Servier. According to the news reported on Reuters, * LIGAND ANNOUNCES AN EXPANSION OF VERNALIS COLLABORATION WITH SERVIER FOR RESEARCH ON NOVEL ONCOLOGY TARGETS

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.57% and up 3.61% for month. Its quarterly performance was 18.07% above, while its half year performance is up 30.70%. LGND yearly performance stood at positive 31.75% and rise 13.08% for year-to-date. Current recommendation for Ligand Pharmaceuticals Incorporated is 2.20.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. LGND EPS (TTM) for 12-month is -3.44. EPS for this year is 432.60%, while for the next year its value is 4.25. Its EPS Q/Q reached -104.70%. It has an EPS of 124.30% up for past five years and for the next five years will be up 18.63%.

Let’s take a look on the analyst recommendations on LGND for the current month and previous month. For the current month, 6 of 8 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $145.00 – $229.00. Average target price for LGND was reached at $184.00.

The insider ownership moved to 4.10%.

The company posted an EPS (TTM) of -3.44. According to the most recent quarter report on (Sep 2020), 6 analysts estimated an average EPS of 0.85, while 0.49 EPS posted a year ago period. Analyst Estimated EPS for LGND published in the report was $0.73 – $1.03 during the same period. Comparing with last year, the average estimated EPS was 0.49 which is lower than 1 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for LGND rise 15.68% for period of 200 days. SMA for 50 days was 2.38% which is showing green signal, while SMA-20 was -1.36%. The moving average value for Ligand Pharmaceuticals Incorporated (LGND) is 9.45M and 54.99% for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in LGND stock. On Jun 04, Berkman Charles S, SVP, Gen. Counsel & Secretary, sold 11,146 trading shares at the cost of $118.59, which valued at 1.32 million. On Feb 27, FOEHR MATTHEW W, President and COO, sold 7,225 shares at the cost of $110.00, with total shares of 153,743. On Feb 14, FOEHR MATTHEW W, President and COO, sold 7,225 shares at the cost of 95.84. After this transaction, FOEHR MATTHEW W total shares reached to 156,229 which valued at 0.69 million.